University of Edinburgh Pre Companies include:
Palpation Diagnostics is a proposed spin-out, developing the ProstaPalp technology, a simple mechanical device which can measure the stiffness of the prostate during a routine digital rectal examination (DRE).
The technology has been developed over the last 17 years by a specialist clinical team at the Western General Hospital in Edinburgh and a strong engineering group at Heriot-Watt University.
When a patient undergoes a DRE the sensor will provide a quantitative assessment of the prostate and algorithms within the base unit will provide a likelihood of cancer being present.
ProstaPalp aims to reduce the number of unnecessary biopsies and also help to identify where a biopsy should be taken. This could result in better health outcomes for patients and savings for the healthcare provider.
Women undergo a ’smear’ test every few years to detect early signs of cervical cancer. An ‘abnormal’ result leads to referral for invasive clinical examination (colposcopy). However, due to the limitations of current screening tests, two out of three women are unnecessarily referred for these examinations.
The proposed spin-out, Precidar Diagnostics (Precidar Dx), led by researchers from the University of Edinburgh, is developing a novel diagnostic test that may rapidly identify these women and allow them to be removed from the clinical care pathway.